

Sarah Jefferies

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1273809/publications.pdf>

Version: 2024-02-01

23
papers

1,144
citations

567281

15
h-index

713466

21
g-index

24
all docs

24
docs citations

24
times ranked

2188
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of the COVID-19 nonpharmaceutical interventions on influenza and other respiratory viral infections in New Zealand. <i>Nature Communications</i> , 2021, 12, 1001.	12.8	268
2	COVID-19 in New Zealand and the impact of the national response: a descriptive epidemiological study. <i>Lancet Public Health</i> , The, 2020, 5, e612-e623.	10.0	220
3	Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: A phase-II parallel non-randomized and observation study (EORTC 22042-26042). <i>Radiotherapy and Oncology</i> , 2018, 128, 260-265.	0.6	123
4	Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand. <i>Nature Communications</i> , 2020, 11, 6351.	12.8	100
5	Genomic Evidence of In-Flight Transmission of SARS-CoV-2 Despite Predeparture Testing. <i>Emerging Infectious Diseases</i> , 2021, 27, 687-693.	4.3	58
6	PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status. <i>Clinical and Translational Radiation Oncology</i> , 2018, 8, 12-16.	1.7	51
7	Treatment options for progression or recurrence of glioblastoma: a network meta-analysis. <i>The Cochrane Library</i> , 2021, 2021, CD013579.	2.8	46
8	Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis. <i>The Cochrane Library</i> , 2020, 2020, CD013261.	2.8	37
9	<i>MGMT</i> promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review. <i>Neuro-Oncology</i> , 2021, 23, 1457-1469.	1.2	36
10	Analysis of heterogeneity in T2-weighted MR images can differentiate pseudoprogression from progression in glioblastoma. <i>PLoS ONE</i> , 2017, 12, e0176528.	2.5	34
11	Use of Genomics to Track Coronavirus Disease Outbreaks, New Zealand. <i>Emerging Infectious Diseases</i> , 2021, 27, 1317-1322.	4.3	28
12	Prevalence of <i>BRAF</i> V600 in glioma and use of <i>BRAF</i> Inhibitors in patients with <i>BRAF</i> V600 mutation-positive glioma: systematic review. <i>Neuro-Oncology</i> , 2022, 24, 528-540.	1.2	26
13	Local alkylating chemotherapy applied immediately after 5-ALA guided resection of glioblastoma does not provide additional benefit. <i>Journal of Neuro-Oncology</i> , 2018, 136, 273-280.	2.9	22
14	Prognostic value of test(s) for O6-methylguanineâ€DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide. <i>The Cochrane Library</i> , 2021, 2021, CD013316.	2.8	19
15	Aspirin does not prevent growth of vestibular schwannomas: A caseâ€control study. <i>Laryngoscope</i> , 2018, 128, 2139-2144.	2.0	16
16	COVID-19 vaccine strategies for Aotearoa New Zealand: a mathematical modelling study. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 15, 100256.	2.9	15
17	Diagnostic accuracy of 1p/19q codeletion tests in oligodendroglioma: A comprehensive metaâ€analysis based on a Cochrane systematic review. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, .	3.2	10
18	Conservative or radical surgery for pediatric papillary thyroid carcinoma: A systematic review of the literature. <i>International Journal of Pediatric Otorhinolaryngology</i> , 2015, 79, 1620-1624.	1.0	8

#	ARTICLE	IF	CITATIONS
19	Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma. The Cochrane Library, 2022, 2022, CD013387.	2.8	8
20	Creating symptom-based criteria for diagnostic testing: a case study based on a multivariate analysis of data collected during the first wave of the COVID-19 pandemic in New Zealand. BMC Infectious Diseases, 2021, 21, 1119.	2.9	6
21	Prognostic value of test(s) for O ⁶ -methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide. The Cochrane Library, 0, , .	2.8	2
22	Treatment options for recurrent glioblastoma: a network meta-analysis. The Cochrane Library, 0, , .	2.8	2
23	Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma. The Cochrane Library, 2019, , .	2.8	1